Request ConsultationThe FDA has raised cardiac safety concerns after identifying four deaths among patients treated with Newron Pharmaceuticals’ experimental schizophrenia drug evenamide. The review could affect clinical trial enrollment, safety monitoring, and the drug’s future development.
The development of new treatments for serious mental health conditions is entering an important phase to help patients who do not respond adequately to existing medications. However, the path from clinical research to regulatory approval depends not only on demonstrating therapeutic benefits but also on establishing an acceptable safety profile.
A recent development involving Newron Pharmaceuticals, has brought this challenge into focus. On October 8, 2026, Reuters reported that the U.S. Food and Drug Administration (FDA) had identified four deaths among patients treated with the company’s. The findings were communicated following an earlier decision to place a clinical hold on new patient enrolment at U.S. sites in a late-stage clinical trial.
The agency’s concerns include the possibility of serious cardiac events associated with irregular heart rhythms. Newron has stated that investigators to evenamide, while one was considered possibly related because autopsy did not establish a definitive cause of death. The FDA nevertheless characterized the cases as a potential safety signal because a fatal arrhythmic mechanism could not be definitively excluded.
The development raises important questions about clinical trial safety, pharmacovigilance, and the evidence required to advance experimental medicine. It also highlights the challenge of evaluating rare but potentially serious events during drug development.
The issue is not simply whether evenamide can improve schizophrenia symptoms. It is whether the available evidence can adequately establish its safety for patients who may require long-term treatment.
What Happened in the Evenamide Clinical Trials?
Newron Pharmaceuticals, an Italy-based biopharmaceutical company, is developing evenamide as a potential treatment for patients with schizophrenia, particularly those with treatment-resistant schizophrenia.
According to Reuters, the FDA identified four deaths among patients who had received evenamide across the clinical development programs, compared with one death among patients receiving placebo. The agency raised concerns about the possibility that the death could involve a fatal cardiac arrhythmia, or an abnormal heart rhythm.
The distinction between a reported death and a confirmed drug-related death is improtantn. A serious event occurring during a clinical trial does not automatically establish that the investigational medicine caused it. Investigators must evaluate the available clinical information, medical history, timing, diagnostic findings, and other possible explanations.
In this case, Newron reported that three of the four deaths among evenamide-treated patients were considered unrelated to the drug by the study investigators. This fourth was considered possibly related because two autopsies did not identify a definitive cause of death.
However, the FDA’s concerns were that a fatal arrhythmic mechanism could not be conclusively ruled out. This uncertainty was sufficient to raise a potential safety signal requiring further assessment.
The clinical hold remains in place at U.S. study centers, preventing new patient enrollment in the affected trial at those sites. Newron is reviewing the FDA’s feedback and the broader safety data before preparing its response. Enrollment continues outside the United States, according to the company.
The development illustrates how regulators may require additional evidence even when investigators have not established a direct causal relationship between an investigational drug and every reported death
Understanding Evenamide and It's Potential Role in Schizophrenia Treatment
Schizophrenia is a serious mental health condition that can affect thinking, perception, emotional responses, and everyday functioning. Although existing antipsychotic medicines help many patients, some individuals experience an inadequate response despite receiving treatment.
Treatment-resistant schizophrenia represents a particularly challenging. clinical population. Patients may continue to experience symptoms even after receiving appropriate treatment with established medicines, creating a need for additional therapeutic options.
Evenamide is being investigated as an add-on treatment for patients whose schizophrenia remains inadequately controlled. It acts as a glutamate modulator through selective blockade of voltage-gated sodium channels.
This mechanism differs from the primary actions of many established antipsychotic medicines. The development program is investigating whether evenamide could provide additional benefits when used alongside existing treatment.
The potential clinical opportunity is significant because treatment-resistant schizophrenia can be associated with persistent symptoms, substantial care requirements, and reduced quality of life. A treatment that provides meaningful additional symptom control could address an important unmet medical need.
However, a novel mechanism of action also requires careful evaluation of potential risks. A drug’s therapeutic rationale does not eliminate the need to investigate its effects on the cardiovascular system, nervous system, and other physiological functions.
Why is the FDA Concerned About Cardiac Safety?
The FDA concerns relate to the possibility that certain sodium channel blockers may trigger arrhythmias, potentially resulting in serious cardiovascular events or seizures.
Voltage-gated sodium channels help regulate electrical signaling in cells, including nerve and cardiac cells. Medicines that affect sodium channel activity can have different physiological effects depending on their selectivity, exposure levels, and other pharmacological properties.
Consequently, the cardiac safety profile of an investigational sodium channel blocker requires careful evaluation, particularly when reports of sudden or unexplained deaths emerge during clinical development.
Newron has also reported that evenamide can produce a very small shortening of the QTc interval on an electrocardiogram (ECG). The QTc interval represents the time required for the heart’s electrical system to undergo ventricular depolarization and repolarization, adjusted for heart rate.
Changes in the QTc interval can provide important information during drug safety assessments. QTc prolongation is an established concern for certain medicines because it can be associated with potentially dangerous arrhythmias.
QTc shortening presents a different interpretive challenge. According to Newron’s account of the FDA feedback, there is no established risk-of-intervention threshold for QTc shortening comparable to the commonly used thresholds for QTc prolongation.
Furthermore, a routine screening ECG cannot reliably exclude every underlying sodium channel disorder in an asymptomatic person.
This means that a normal screening result may not be sufficient to rule out all potential cardiac vulnerabilities. Regulators may therefore need to examine the broader clinical evidence, including the circumstances surrounding reported deaths and any available electrophysiology assessments.
The FDA’s concern does not establish that evenamode caused the four deaths. Rather, it reflects the need to investigate whether an important safety risk can be excluded with sufficient confidence.
Why the Four Deaths Matter for Pharmacovigilance
Pharmacovigilance involves detecting, assessing, understanding, and preventing adverse effects associated with medicines. During clinical development, these activities help researchers and regulators identify potential risks before a treatment becomes widely available.
The evenamide case demonstrates why pharmacovigilance cannot rely exclusively on investigators' initial assessments of individual events.
A death may be classified as unrelated, possibly related, or of uncertain causality based on the information available at the time. However, regulators can also evaluate events collectively to determine whether they indicate a broader pattern that warrants further investigation.
This distinction is especially important when events are rare but potentially life-threatening.
Several aspects of the evenamide safety review are relevant to clinical drug development:
- Serious adverse event assessment: Deaths and other life-threatening events require detailed documentation, medical review, and evaluation of alternative explanations.
- Causality assessment: Investigators must assess whether the timing, clinical circumstances, and available evidence support a possible relationship with the investigational medicine.Signal detection: Multiple events may require further analysis even when a direct causal relationship has not been established for every case.
- Aggregate safety review: Investigators and sponsors need to examine safety information across clinical trials rather than treating each event as an isolated occurrence.
- Regulatory communication: Emerging concerns must be evaluated and communicated to the relevant authorities so that appropriate decisions can be made about trial continuation.
A potential safety signal is not equivalent to proof of causation. It is an indication that available evidence warrants closer examination.
For pharmaceutical companies, the challenge is to investigate the signal thoroughly while maintaining accurate, transparent safety documentation. For regulators, the priority is to determine whether continued exposure to the investigational treatment is justified under the existing study conditions.
The Importance of Clinical Trial Holds
A clinical hold is a regulatory measure that can restrict or suspend a clinical investigation when concerns arise about participant safety or the adequacy of the available information.
In the evenamide case, the FDA previously placed a hold on new patient enrollment at U.S. sites in a Phase 3 study after a patient's sudden death. The subsequent feedback identified four deaths across the broader evenamide clinical development program and raised further questions about potential cardiac risks.
A clinical hold does not necessarily mean that a medicine has failed its clinical development program or that it can never receive approval. Instead, it indicates that the regulator requires the relevant concerns to be addressed before the affected study activities can proceed under the applicable conditions.
Depending on the circumstances, a sponsor may need to provide additional analyses, clarify the circumstances surrounding adverse events, review the monitoring strategt, or purpose changes to the study protocol.
For Newron, the next step is to evaluate the FDA's written feedback and prepare a response based on the full body of available evidence.
The outcome will depend on whether the company can adequately address the agency's concerns. The FDA may need to determine whether the evidence supports resuming enrollment, whether additional safeguards are necessary, or whether further investigation is required.
Until the concerns are resolved, the clinical hold remains an important constraint on the U.S. development program.
Newron's Safety Data and the Need for Further Evaluation
Newron has stated that it has not identified a pattern of heart abnormalities or irregular rhythms in its preclinical and clinical safety data.
The company also reported that its development program includes more than 10,000 ECGs from approximately 700 evenamide-treated subjects, together with input from independent cardiac electrophysiologists.
These data are relevant because a comprehensive safety assessment requires more than counting reported events. Researchers must evaluate the overall exposure to the medicine, the nature of the reported outcomes, the characteristics of affected patients, and the consistency of findings across studies.
Newron reported four deaths among evenamide-treated patients, representing an incidence of 0.56%, compared with one death among placebo recipients, representing an incidence of 0.27%.
The company also provided treatment-duration-adjusted mortality rates of 1.31 per 100 patient-years for evenamide and 1.81 per 100 patient-years for placebo.
These figures provide additional context, but they should not be interpreted as definitive proof that the drug is safe or that it caused the reported deaths. The groups may differ in treatment duration and other characteristics, and the small number of events limits the conclusions that can be drawn from the comparison.
Likewise, the absence of a clear pattern in ECG data does not automatically resolve every possible concern about rare arrhythmias.
The FDA must consider the totality of the evidence, including individual case details, aggregate findings, pharmacological information, and the limitations of the available data.Further evaluation may help clarify whether the reported deaths represent unrelated events, a treatment-associated risk, or a safety concern that cannot yet be adequately characterized.
What This Means for Phase 3 Clinical Development
Late-stage clinical trials are designed to generate the evidence needed to evaluate a medicine's efficacy and safety in a larger patient population.
Evenamide is being studied in the Phase 3 ENIGMA-TRS program, which includes trials evaluating its potential use in treatment-resistant schizophrenia.
The ENIGMA-TRS 2 study is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy, tolerability, and safety of evenamide at a dose of 15 mg twice daily. Its primary efficacy assessment focuses on changes in Positive and Negative Syndrome Scale (PANSS) scores after 12 weeks.
The FDA's concerns introduce an additional regulatory challenge for this development program.
First, the company must address the safety questions raised by the agency. This process may require detailed analyses of the reported deaths and the wider cardiac safety dataset.
Second, the clinical development timeline may be affected. Enrollment restrictions at U.S. sites can influence recruitment, site operations, and the availability of data from the affected locations.
Third, the findings could influence how investigators evaluate patient eligibility and safety monitoring, depending on the conclusions reached during the review.
However, the precise impact on timelines and study requirements remains uncertain. The company has not established that the drug caused the deaths, and the final regulatory outcome will depend on the assessment of the available evidence.
Newron has stated that enrollment in ENIGMA-TRS 1 was expected to be completed by mid-October 2026, with topline 12-week data anticipated in the first quarter of 2027. Enrollment in ENIGMA-TRS 2 continues outside the United States.
These milestones remain important to the development program, although the broader implications of the safety review will depend on subsequent regulatory discussions and findings.
The Role of ECG Monitoring and Risk Management
Cardiac monitoring is an important component of clinical trials involving medicines with potential cardiovascular effects.
ECGs can help investigators identify electrical abnormalities and monitor changes during treatment. Depending on the medicine and its known risks, clinical protocols may also include laboratory testing, medical history reviews, eligibility criteria, and additional assessments when symptoms or abnormal findings emerge.
However, monitoring strategies must be appropriate to the specific mechanism of action and potential adverse events.
The evenamide case illustrates a limitation of relying on a single screening measure. If a possible risk involves an underlying sodium channel disorder that may not be apparent on a routine ECG, a normal initial result cannot necessarily exclude that vulnerability.
Further evaluation may therefore need to consider whether the existing screening and monitoring procedures adequately address the concern identified by the FDA.
Potential changes to trial procedures would need to be determined through scientific assessment and regulatory consultation rather than assumed in advance.
The broader lesson for drug developers is that safety monitoring must evolve when new evidence identifies a potential risk that was not fully understood at the beginning of a clinical program.
Implications for the Pharmaceutical Industry
The FDA's review of evenamide highlights several issues that extend beyond a single investigational medicine.
Patient safety remains the primary consideration. An investigational drug may address an important unmet medical need, but its potential benefits must be evaluated against the risks identified during development.
Rare events require careful interpretation. Small numbers of serious events can create substantial uncertainty. Researchers must avoid both prematurely attributing causality and dismissing a potential risk because the available evidence is inconclusive.
Comprehensive safety data are essential. Clinical development depends on high-quality adverse event documentation, consistent medical review, aggregate analyses, and timely regulatory communication.
Regulatory decisions can influence development timelines. A clinical hold may affect enrollment, study operations, and the timing of data readouts, even when a medicine remains under investigation.
Transparent communication matters. Sponsors must explain what is known, what remains uncertain, and how they intend to address regulators' questions.
These considerations are particularly important for medicines intended for long-term use. Establishing an acceptable safety profile requires evaluating not only whether a treatment works but also whether its risks can be understood and managed in the intended patient population.
Key Challenges Ahead
The next stage of evenamide's development will depend on how effectively the outstanding safety questions are addressed.
- Causality Uncertainty: The available evidence has not established that evenamide caused all four deaths, but a fatal arrhythmic mechanism has not been definitively excluded.
- Cardiac Risk Assessment: The relationship between sodium channel blockade, QTc shortening, and the reported outcomes requires careful scientific evaluation.
- Clinical Trial Continuity: The U.S. enrollment hold may affect recruitment and the operational progress of the affected study.
- Safety Monitoring: The adequacy of existing screening procedures and monitoring strategies may need further consideration.
- Regulatory Requirements: Newron must review the FDA's feedback and provide an evidence-based response before the status of the U.S. study can be clarified.
- Development Timelines: The effect of the safety review on future milestones remains uncertain and will depend on the regulatory outcome.
Addressing these issues will be important for determining whether the clinical program can advance under acceptable safety conditions.
What Could Happen Next?
The future of evenamide's development could follow several paths depending on the outcome of the safety review.
In one scenario, additional analyses could provide sufficient reassurance that the reported deaths do not establish an unacceptable treatment-associated risk. The FDA could then consider whether the U.S. trial can resume, potentially with appropriate conditions or safeguards.
In another scenario, the evidence could remain inconclusive. The company might need to conduct additional analyses, provide further clinical information, or discuss changes to its development strategy with regulators.
A more difficult outcome would arise if the review identified a credible risk that could not be adequately mitigated. Such findings could require more substantial changes to the clinical program or affect the medicine's prospects for further development.
These are possible outcomes rather than confirmed regulatory decisions. No conclusion about the final status of evenamide can be drawn from the reported deaths alone.The company's response to the FDA and the agency's subsequent assessment will be central to determining the next steps.
Conclusion
The FDA's identification of four deaths among patients treated with Newron Pharmaceutical experimental schizophrenia drug evenamide highlights the complex relationship between therapeutic innovation and drug safety.
The findings have raised concerns about a possible cardiac risk, including the potential for fatal arrhythmias. Although investigators considered three of the four deaths unrelated to the medicine and one possibly related, the FDA determined that a fatal arrhythmic mechanism could not be definitively excluded.
The distinction is critical. A potential safety signal does not establish causation, but it can justify further investigation when the consequences could be serious.
For Newron, the immediate priority is to review the FDA's feedback, assess the available clinical evidence, and determine how the outstanding concerns can be addressed. The continued enrollment of patients outside the United States and the hold at U.S. study centers illustrate how regulatory decisions can differ across trial locations while safety questions remain under review.
The case also reinforces the importance of pharmacovigilance throughout clinical development. Detailed case assessment, aggregate safety analysis, appropriate cardiac monitoring, and transparent regulatory communication are essential to identifying and evaluating potential risks.
Evenamide is being investigated for a patient population with significant unmet medical needs. Its future will depend on whether the clinical program can demonstrate a meaningful therapeutic benefit alongside an acceptable safety profile.
Ultimately, the FDA's review is a reminder that successful drug development requires more than promising efficacy results. Medicines must also meet rigorous standards for safety, supported by evidence that can withstand careful scientific and regulatory scrutiny.
The next phase of evenamide's development will therefore depend on a central question: can the remaining safety uncertainty be resolved sufficiently to justify continued clinical investigation?
About the Authors
Aditi Shivarkar
Aditi, Vice President at Precedence Research, brings over 15 years of expertise at the intersection of technology, innovation, and strategic market intelligence. A visionary leader, she excels in transforming complex data into actionable insights that empower businesses to thrive in dynamic markets. Her leadership combines analytical precision with forward-thinking strategy, driving measurable growth, competitive advantage, and lasting impact across industries.
Aman Singh
Aman Singh with over 13 years of progressive expertise at the intersection of technology, innovation, and strategic market intelligence, Aman Singh stands as a leading authority in global research and consulting. Renowned for his ability to decode complex technological transformations, he provides forward-looking insights that drive strategic decision-making. At Precedence Research, Aman leads a global team of analysts, fostering a culture of research excellence, analytical precision, and visionary thinking.
Piyush Pawar
Piyush Pawar brings over a decade of experience as Senior Manager, Sales & Business Growth, acting as the essential liaison between clients and our research authors. He translates sophisticated insights into practical strategies, ensuring client objectives are met with precision. Piyush’s expertise in market dynamics, relationship management, and strategic execution enables organizations to leverage intelligence effectively, achieving operational excellence, innovation, and sustained growth.